MA28003A1 - [1,8] naphtyridine-2-ones et composes apparentes pour le traitement de la schizophrenie - Google Patents
[1,8] naphtyridine-2-ones et composes apparentes pour le traitement de la schizophrenieInfo
- Publication number
- MA28003A1 MA28003A1 MA28828A MA28828A MA28003A1 MA 28003 A1 MA28003 A1 MA 28003A1 MA 28828 A MA28828 A MA 28828A MA 28828 A MA28828 A MA 28828A MA 28003 A1 MA28003 A1 MA 28003A1
- Authority
- MA
- Morocco
- Prior art keywords
- naphthyridine
- schizophrenia
- ones
- treatment
- related compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Virology (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Anesthesiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
DEPOSANT Société dite : WARNER-LAMBERT COMPANY LLC REVENDICATION DE PRIORITES US 22 Août 2003 60/497,370 Voir en annexe le titre de l'invention et le texte de l'abrégé
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49737003P | 2003-08-22 | 2003-08-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28003A1 true MA28003A1 (fr) | 2006-07-03 |
Family
ID=34216117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA28828A MA28003A1 (fr) | 2003-08-22 | 2006-02-22 | [1,8] naphtyridine-2-ones et composes apparentes pour le traitement de la schizophrenie |
Country Status (36)
Country | Link |
---|---|
US (3) | US7160888B2 (fr) |
EP (1) | EP1660497A1 (fr) |
JP (1) | JP4034811B2 (fr) |
KR (2) | KR100801794B1 (fr) |
CN (1) | CN100422181C (fr) |
AP (1) | AP2006003525A0 (fr) |
AR (1) | AR045386A1 (fr) |
AU (1) | AU2004266191B2 (fr) |
BR (1) | BRPI0413860A (fr) |
CA (1) | CA2538915C (fr) |
CR (2) | CR8254A (fr) |
CU (1) | CU23464B7 (fr) |
EA (1) | EA009645B1 (fr) |
EC (1) | ECSP066391A (fr) |
GE (1) | GEP20084447B (fr) |
GT (1) | GT200500007A (fr) |
HK (1) | HK1091815A1 (fr) |
HN (1) | HN2004000319A (fr) |
IL (1) | IL173439A0 (fr) |
IS (1) | IS8267A (fr) |
MA (1) | MA28003A1 (fr) |
ME (1) | MEP45308A (fr) |
MX (1) | MXPA06002070A (fr) |
MY (1) | MY140693A (fr) |
NL (1) | NL1026892C2 (fr) |
NO (1) | NO20060324L (fr) |
NZ (1) | NZ545078A (fr) |
OA (1) | OA13238A (fr) |
PA (1) | PA8609701A1 (fr) |
PE (1) | PE20051039A1 (fr) |
RS (1) | RS20060129A (fr) |
TN (1) | TNSN06063A1 (fr) |
TW (1) | TWI298327B (fr) |
UA (1) | UA82541C2 (fr) |
WO (1) | WO2005019215A1 (fr) |
ZA (1) | ZA200601526B (fr) |
Families Citing this family (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE46117E1 (en) | 1999-12-22 | 2016-08-23 | Teva Pharmaceuticals International Gmbh | Modulators of dopamine neurotransmission |
SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
SE9904723D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission II |
US7504395B2 (en) * | 2001-07-20 | 2009-03-17 | Psychogenics, Inc. | Treatment for attention-deficit hyperactivity disorder |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
DE602005017784D1 (de) | 2004-06-08 | 2009-12-31 | Nsab, Filial Af Neurosearch Sweden Ab | Neue disubstituierte phenylpiperidine als modulatoren der dopamin- und serotoninneurotransmission |
US7851629B2 (en) | 2004-06-08 | 2010-12-14 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission |
DK1773772T3 (da) * | 2004-06-08 | 2010-09-13 | Nsab Af Neurosearch Sweden Ab | Nye disubstituerede phenylpiperidiner/piperaziner som modulatorer af dopaminneurotransmission |
EP1802573B1 (fr) | 2004-10-13 | 2016-09-28 | Teva Pharmaceuticals International GmbH | Procede de synthese de 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine |
FR2877005A1 (fr) * | 2004-10-22 | 2006-04-28 | Bioprojet Soc Civ Ile | Nouveaux derives d'arylpiperazine |
US7511035B2 (en) | 2005-01-25 | 2009-03-31 | Glaxo Group Limited | Antibacterial agents |
WO2006090272A1 (fr) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | Isoquinoline [1,8]naphthyridin-2-ones et composes relatifs destines au traitement de la schizophrenie |
WO2006090273A2 (fr) * | 2005-02-22 | 2006-08-31 | Warner-Lambert Company Llc | [1,8]naphthyridin-2-ones et composes relatifs a liants ceto ou hydroxyl destines au traitement de la schizophrenie |
MX2007012083A (es) * | 2005-04-01 | 2007-11-20 | Warner Lambert Co | Tetrahidro-piridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia. |
ES2520015T3 (es) * | 2005-04-08 | 2014-11-11 | Pfizer Products Inc. | [3.1.0]Heteroaril amidas bicíclicas como inhibidores de transporte de glicina de tipo 1 |
TWI320783B (en) * | 2005-04-14 | 2010-02-21 | Otsuka Pharma Co Ltd | Heterocyclic compound |
JP4315393B2 (ja) * | 2005-04-14 | 2009-08-19 | 大塚製薬株式会社 | 複素環化合物 |
AR055203A1 (es) | 2005-08-31 | 2007-08-08 | Otsuka Pharma Co Ltd | Derivados de benzotiofeno con propiedades antipsicoticas |
AU2006302148B2 (en) | 2005-10-07 | 2012-12-06 | Exelixis, Inc. | Pyridopyrimidinone inhibitors of PI3Kalpha |
SE529246C2 (sv) | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
WO2007052104A2 (fr) * | 2005-10-31 | 2007-05-10 | Pfizer Products Inc. | Sels cristallins de 7-[4-(4-naphtalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1h-[1,8]naphtyridin-2-one |
US7935706B2 (en) | 2006-02-23 | 2011-05-03 | Shionogi & Co., Ltd. | Nitrogen-containing heterocycle derivatives substituted with cyclic group |
WO2007116265A1 (fr) * | 2006-03-31 | 2007-10-18 | Pfizer Products Inc. | Procede de fabrication d'un compose de tetrahydro-pyridoazepin-8-one |
EP2027087A2 (fr) | 2006-05-18 | 2009-02-25 | MannKind Corporation | Inhibiteurs de kinases intracellulaires |
SI2074122T1 (sl) * | 2006-09-15 | 2011-10-28 | Pfizer Prod Inc | Pirido (2,3-d)pirimidinonske spojine in njihova uporaba kot zaviralci PI3 |
US20100093738A1 (en) * | 2006-10-06 | 2010-04-15 | Basf Se | Fungicidal Compounds and Fungicidal Compositions |
AR063302A1 (es) * | 2006-10-13 | 2009-01-21 | Otsuka Pharma Co Ltd | Derivados de 4-benzo[b]tiofen-4-il-piperazin-1-il con accion antagonista del receptor 5-ht2a de serotonina y receptor de adrenalina alfa1 y agonista parcial del receptor d2, una composicion farmaceutica que lo comprende y un proceso para producirla. |
JP4540700B2 (ja) * | 2006-10-13 | 2010-09-08 | 大塚製薬株式会社 | 医薬 |
WO2008084324A1 (fr) * | 2007-01-04 | 2008-07-17 | Pfizer Products Inc. | Composé de naphtyridinone |
JP4785881B2 (ja) * | 2007-02-27 | 2011-10-05 | 大塚製薬株式会社 | 医薬 |
CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
RU2497819C2 (ru) * | 2007-05-21 | 2013-11-10 | Ривайва Фармасьютикалс, Инк. | Композиции, синтез и способы применения атипичных нейролептиков на основе хинолина |
WO2008150848A1 (fr) * | 2007-05-30 | 2008-12-11 | Wyeth | Dérivés d'hétéro-aryle antidépresseurs de benzodioxanes condensés avec un hétérocycle |
US7928111B2 (en) * | 2007-06-08 | 2011-04-19 | Senomyx, Inc. | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors |
MX2010006111A (es) | 2007-12-18 | 2010-06-25 | Actelion Pharmaceuticals Ltd | Derivados de 5-aminociclilmetil-oxazolidin-2-ona y su uso como antibacteriales. |
US8653069B2 (en) | 2008-07-28 | 2014-02-18 | Jiangsu Hengyi Pharmaceutical Co., Ltd. | Aralkyl substituted piperidine or piperazine derivatives and their use for treating schizophrenia |
ES2647947T3 (es) | 2008-07-31 | 2017-12-27 | Senomyx, Inc. | Procesos y productos intermedios para la preparación de potenciadores del sabor dulce |
SI2376497T1 (sl) | 2008-12-12 | 2014-01-31 | Actelion Pharmaceuticals Ltd. | Derivati 5-amino-2-(1-hidroksi-etil)-tetrahidropirana |
WO2010085570A1 (fr) * | 2009-01-23 | 2010-07-29 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la poly(adp-ribose)polymérase (parp) |
KR101705727B1 (ko) * | 2009-02-26 | 2017-02-10 | 레비바 파마슈티칼스, 아이엔씨. | 아릴피페라진 유도체의 조성물, 합성, 및 사용 방법 |
WO2010151711A1 (fr) | 2009-06-25 | 2010-12-29 | Alkermes, Inc. | Promédicaments de composés nh acides |
HRP20171415T4 (hr) * | 2009-06-25 | 2023-03-03 | Alkermes Pharma Ireland Limited | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja |
ES2834973T3 (es) | 2010-05-04 | 2021-06-21 | Alkermes Pharma Ireland Ltd | Procedimiento de síntesis de compuestos de lactama oxidada |
EP2585066B1 (fr) | 2010-06-24 | 2018-09-26 | Alkermes Pharma Ireland Limited | Promédicaments de composés nh-acides : dérivés esters, carbonates, carbamates et phosphonates |
US9156822B2 (en) | 2010-07-02 | 2015-10-13 | The University Of North Carolina At Chapel Hill | Functionally selective ligands of dopamine D2 receptors |
MA34836B1 (fr) | 2010-12-17 | 2014-01-02 | Hoffmann La Roche | Composes heterocycliques azotes 6;6- condenses substitues et leurs utilisations |
US9034867B2 (en) | 2011-03-18 | 2015-05-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising sorbitan esters |
JO3227B1 (ar) * | 2011-09-08 | 2018-03-08 | Otsuka Pharma Co Ltd | مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان |
US9012476B2 (en) | 2011-12-08 | 2015-04-21 | IVAX International GmbH | Hydrobromide salt of pridopidine |
NZ722096A (en) | 2011-12-15 | 2016-11-25 | Alkermes Pharma Ireland Ltd | Prodrugs of secondary amine compounds |
CA2867137C (fr) | 2012-03-19 | 2020-12-08 | Alkermes Pharma Ireland Limited | Compositions pharmaceutiques renfermant des promedicaments d'aripiprazole et d'alcool benzylique |
JP6471089B2 (ja) | 2012-03-19 | 2019-02-13 | アルカームス ファーマ アイルランド リミテッド | 脂肪酸エステルを含む医薬組成物 |
JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
EA027748B1 (ru) | 2012-04-04 | 2017-08-31 | Тева Фармасьютикалз Интернэшнл Гмбх | Применение придопидина в комбинации с тетрабеназином для лечения двигательных нарушений и ожирения |
US9951088B2 (en) | 2012-05-09 | 2018-04-24 | Sunovion Pharmaceuticals Inc. | D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders |
ES2792149T3 (es) | 2012-09-19 | 2020-11-10 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada |
MX2016012041A (es) | 2014-03-20 | 2017-01-19 | Alkermes Pharma Ireland Ltd | Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion. |
CN104785295B (zh) * | 2015-03-18 | 2018-03-06 | 杭州创培信息科技有限公司 | 一种高选择性多巴胺铂炭催化剂的制备方法 |
US9902703B2 (en) | 2015-07-01 | 2018-02-27 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
ES2879995T3 (es) | 2015-12-10 | 2021-11-23 | Ptc Therapeutics Inc | Métodos para el tratamiento de la enfermedad de Huntington |
CN106242934A (zh) * | 2016-07-26 | 2016-12-21 | 云南民族大学 | 一种酮的β‑位C‑H键乙酰氧化合成方法 |
AU2018282154B2 (en) * | 2017-06-05 | 2022-04-07 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
WO2019005980A1 (fr) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Procédés de traitement de la maladie de huntington |
BR112019027719A2 (pt) | 2017-06-28 | 2020-07-28 | Ptc Therapeutics, Inc. | métodos para tratar a doença de huntington |
US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
JP7384812B2 (ja) | 2018-03-05 | 2023-11-21 | アルカームス ファーマ アイルランド リミテッド | アリピプラゾール投与戦略 |
WO2019170543A1 (fr) | 2018-03-07 | 2019-09-12 | Bayer Aktiengesellschaft | Identification et utilisation d'inhibiteurs d'erk5 |
KR20210005559A (ko) | 2018-03-27 | 2021-01-14 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료 화합물 |
US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
AU2019294478B2 (en) | 2018-06-27 | 2023-03-23 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating Huntington's disease |
MX2021001193A (es) | 2018-08-07 | 2021-04-28 | Firmenich Incorporated | 2,2-dioxidos de 4-amino-1h-benzo[c][1,2,6]tiadiazina 5-sustituidos y formulaciones y usos de los mismos. |
PE20211089A1 (es) | 2018-08-13 | 2021-06-14 | Hoffmann La Roche | Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa |
US11066404B2 (en) | 2018-10-11 | 2021-07-20 | Incyte Corporation | Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors |
US11384083B2 (en) | 2019-02-15 | 2022-07-12 | Incyte Corporation | Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors |
WO2020180959A1 (fr) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Composés de pyrazolyl pyrimidinylamine en tant qu'inhibiteurs de cdk2 |
WO2020205560A1 (fr) | 2019-03-29 | 2020-10-08 | Incyte Corporation | Composés sulfonylamides utilisés comme inhibiteurs de la cdk2 |
WO2020223469A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer |
WO2020223558A1 (fr) | 2019-05-01 | 2020-11-05 | Incyte Corporation | Composés aminés tricycliques en tant qu'inhibiteurs de cdk2 |
EP4013750A1 (fr) | 2019-08-14 | 2022-06-22 | Incyte Corporation | Composés imidazolyl-pyrimidinylamines utilisés comme inhibiteurs de la cdk2 |
BR112022002375A2 (pt) | 2019-09-12 | 2022-07-19 | Hoffmann La Roche | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl |
WO2021072232A1 (fr) | 2019-10-11 | 2021-04-15 | Incyte Corporation | Amines bicycliques utilisées en tant qu'inhibiteurs de cdk2 |
CN114634479A (zh) * | 2020-12-16 | 2022-06-17 | 北京盈科瑞创新药物研究有限公司 | 一种派嗪衍生物、其制备方法及应用 |
WO2022212538A1 (fr) * | 2021-03-31 | 2022-10-06 | Blueprint Medicines Corporation | Composés pyrimidines condensés avec la diazépanone, compositions et leurs applications médicales |
US11981671B2 (en) | 2021-06-21 | 2024-05-14 | Incyte Corporation | Bicyclic pyrazolyl amines as CDK2 inhibitors |
US11976073B2 (en) | 2021-12-10 | 2024-05-07 | Incyte Corporation | Bicyclic amines as CDK2 inhibitors |
CN116891465A (zh) * | 2022-03-30 | 2023-10-17 | 苏州旺山旺水生物医药有限公司 | 一类n-取代的喹啉酮化合物、其制备方法和用途 |
CN114805081A (zh) * | 2022-05-20 | 2022-07-29 | 都创(上海)医药开发有限公司 | 一种基于微通道连续流技术快速制备1-萘胺的方法 |
Family Cites Families (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5649361A (en) | 1979-09-28 | 1981-05-02 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
JPH07165720A (ja) * | 1988-10-31 | 1995-06-27 | Otsuka Pharmaceut Co Ltd | カルボスチリル誘導体及び該誘導体を含有する精神***病治療剤 |
JP2608788B2 (ja) * | 1988-10-31 | 1997-05-14 | 大塚製薬 株式会社 | 精神***病治療剤 |
WO1990006303A1 (fr) | 1988-12-02 | 1990-06-14 | Pfizer Inc. | Derives arylpiperidine |
ES2076253T3 (es) | 1989-05-19 | 1995-11-01 | Hoechst Roussel Pharma | N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos. |
WO1991000863A1 (fr) * | 1989-07-07 | 1991-01-24 | Pfizer Inc. | Agents antipsychotiques a base de piperazine d'heteroaryle |
US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
US5032598A (en) | 1989-12-08 | 1991-07-16 | Merck & Co., Inc. | Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents |
MX9201991A (es) * | 1991-05-02 | 1992-11-01 | Jonh Wyeth & Brother Limited | Derivados de piperazina y procedimiento para su preparacion. |
IE914218A1 (en) | 1991-09-11 | 1993-03-24 | Mcneilab Inc | Novel 4-arylpiperazines and 4-arylpiperidines |
US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
TW370529B (en) | 1992-12-17 | 1999-09-21 | Pfizer | Pyrazolopyrimidines |
US6765008B1 (en) | 1992-12-17 | 2004-07-20 | Pfizer Inc | Pyrrolopyrimidines as CRF antagonists |
TW336932B (en) | 1992-12-17 | 1998-07-21 | Pfizer | Amino-substituted pyrazoles |
DK0674631T3 (da) | 1992-12-17 | 2000-04-10 | Pfizer | Substituerede pyrazoler som CRF-antogonister |
KR0170567B1 (ko) | 1992-12-17 | 1999-02-18 | 알렌 제이. 스피겔 | 부신피질자극호르몬-유리 인자 길항물질 활성을 갖는 피라졸 및 피라졸로피리미딘 |
FR2699918B1 (fr) * | 1992-12-30 | 1995-03-17 | Pf Medicament | Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments. |
JPH07247271A (ja) * | 1994-01-21 | 1995-09-26 | Otsuka Pharmaceut Co Ltd | 3,4−ジヒドロカルボスチリル誘導体 |
FR2731222A1 (fr) | 1995-03-02 | 1996-09-06 | Pf Medicament | Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments |
JP2987484B2 (ja) * | 1995-03-16 | 1999-12-06 | 大塚製薬 株式会社 | カルボスチリル誘導体の製造方法 |
JP2900130B2 (ja) * | 1995-03-16 | 1999-06-02 | 大塚製薬株式会社 | カルボスチリル誘導体及び該誘導体を含有する精神***病治療剤 |
IL117923A (en) | 1995-05-03 | 2000-06-01 | Warner Lambert Co | Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds |
EP0839144B1 (fr) | 1995-07-13 | 2001-09-19 | Knoll GmbH | Derives de piperazine utilises comme agents therapeutiques |
WO1997014419A1 (fr) | 1995-10-20 | 1997-04-24 | Flora Inc. | Administration percutanee d'inhibiteurs des recepteurs alpha-adrenergiques |
JPH09241161A (ja) | 1996-03-08 | 1997-09-16 | Nippon Shinyaku Co Ltd | 医 薬 |
US5912256A (en) | 1996-06-20 | 1999-06-15 | Eli Lilly And Company | Compounds having effects on serotonin-related systems |
US5945422A (en) | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
US6498163B1 (en) | 1997-02-05 | 2002-12-24 | Warner-Lambert Company | Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation |
FR2761071B1 (fr) | 1997-03-20 | 1999-12-03 | Synthelabo | Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique |
FR2769912B1 (fr) | 1997-10-16 | 2000-03-10 | Pf Medicament | Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine |
DE19747063A1 (de) * | 1997-10-24 | 1999-04-29 | Basf Ag | 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung |
US6267784B1 (en) | 1998-05-01 | 2001-07-31 | Benz Research And Development Corporation | Intraocular lens and haptics made of a copolymer |
WO2001046177A1 (fr) | 1999-12-20 | 2001-06-28 | Eli Lilly And Company | Derives de benzofuranne |
DE10041574A1 (de) | 2000-08-24 | 2002-03-07 | Merck Patent Gmbh | Chromenonderivate |
WO2002048105A2 (fr) | 2000-11-16 | 2002-06-20 | Wyeth | Derives d'aryloxy-piperidinyle pour le traitement des depressions |
GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
AR032641A1 (es) | 2001-01-29 | 2003-11-19 | Otsuka Pharma Co Ltd | Agonista de subtipo de receptor 5-ht 1a. |
HUP0400344A2 (hu) | 2001-06-29 | 2004-09-28 | H. Lundbeck A/S | Új heteroarilszármazékok, eljárás előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények |
GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
TW200507841A (en) | 2003-03-27 | 2005-03-01 | Glaxo Group Ltd | Antibacterial agents |
US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
-
2004
- 2004-07-28 US US10/900,210 patent/US7160888B2/en not_active Expired - Fee Related
- 2004-08-13 EA EA200600294A patent/EA009645B1/ru not_active IP Right Cessation
- 2004-08-13 MX MXPA06002070A patent/MXPA06002070A/es active IP Right Grant
- 2004-08-13 WO PCT/IB2004/002665 patent/WO2005019215A1/fr active Application Filing
- 2004-08-13 RS RSP-2006/0129A patent/RS20060129A/sr unknown
- 2004-08-13 NZ NZ545078A patent/NZ545078A/en unknown
- 2004-08-13 UA UAA200601890A patent/UA82541C2/uk unknown
- 2004-08-13 GE GEAP20049246A patent/GEP20084447B/en unknown
- 2004-08-13 AU AU2004266191A patent/AU2004266191B2/en not_active Ceased
- 2004-08-13 CA CA2538915A patent/CA2538915C/fr not_active Expired - Fee Related
- 2004-08-13 JP JP2006523707A patent/JP4034811B2/ja not_active Expired - Fee Related
- 2004-08-13 OA OA1200600052A patent/OA13238A/en unknown
- 2004-08-13 EP EP04744287A patent/EP1660497A1/fr not_active Withdrawn
- 2004-08-13 ME MEP-453/08A patent/MEP45308A/xx unknown
- 2004-08-13 AP AP2006003525A patent/AP2006003525A0/xx unknown
- 2004-08-13 KR KR1020077009877A patent/KR100801794B1/ko not_active IP Right Cessation
- 2004-08-13 CN CNB2004800241500A patent/CN100422181C/zh not_active Expired - Fee Related
- 2004-08-13 KR KR1020067003621A patent/KR100765668B1/ko not_active IP Right Cessation
- 2004-08-13 BR BRPI0413860-0A patent/BRPI0413860A/pt not_active IP Right Cessation
- 2004-08-18 PE PE2004000796A patent/PE20051039A1/es not_active Application Discontinuation
- 2004-08-20 TW TW093125196A patent/TWI298327B/zh active
- 2004-08-20 AR ARP040103006A patent/AR045386A1/es not_active Application Discontinuation
- 2004-08-20 HN HN2004000319A patent/HN2004000319A/es unknown
- 2004-08-20 NL NL1026892A patent/NL1026892C2/nl not_active IP Right Cessation
- 2004-08-20 MY MYPI20043415A patent/MY140693A/en unknown
- 2004-08-20 PA PA20048609701A patent/PA8609701A1/es unknown
-
2005
- 2005-01-13 GT GT200500007A patent/GT200500007A/es unknown
-
2006
- 2006-01-20 NO NO20060324A patent/NO20060324L/no not_active Application Discontinuation
- 2006-01-26 IS IS8267A patent/IS8267A/is unknown
- 2006-01-30 IL IL173439A patent/IL173439A0/en unknown
- 2006-02-10 CU CU20060028A patent/CU23464B7/es not_active IP Right Cessation
- 2006-02-21 ZA ZA200601526A patent/ZA200601526B/en unknown
- 2006-02-22 MA MA28828A patent/MA28003A1/fr unknown
- 2006-02-22 EC EC2006006391A patent/ECSP066391A/es unknown
- 2006-02-22 CR CR8254A patent/CR8254A/es unknown
- 2006-02-22 TN TNP2006000063A patent/TNSN06063A1/en unknown
- 2006-08-24 US US11/466,822 patent/US20060287309A1/en not_active Abandoned
- 2006-08-24 US US11/466,828 patent/US20060287310A1/en not_active Abandoned
- 2006-11-08 HK HK06112251.3A patent/HK1091815A1/xx not_active IP Right Cessation
-
2008
- 2008-03-27 CR CR9834A patent/CR9834A/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28003A1 (fr) | [1,8] naphtyridine-2-ones et composes apparentes pour le traitement de la schizophrenie | |
MA28303A1 (fr) | Derives de sulfonamides pour le traitement de maladies | |
IL229304A0 (en) | Compounds 1',3' - dimethomers - 4 - phenyl -3, 4, 5, 6 - tetrahydro - 2h, 1'h, [1, 4'] bipyridinyl - 2' -ones Preparations containing them and their use | |
PT1390031E (pt) | Composicao topica contendo um fungicida | |
IL175992A0 (en) | Substituted arylpyrazoles as parasiticidal agents | |
PT1399127E (pt) | Formulacoes de olopatadina para administracao topica | |
IL186089A0 (en) | 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists | |
GB0125222D0 (en) | Composition for the treatment of microbial infections | |
EP1455804A4 (fr) | Utilisation de nanoparticules en tant qu'excipients pour biocides dans des compositions ophtalmiques | |
IL159434A0 (en) | New derivatives of oxazolidinones as antibacterial agents | |
ITMI20031579A1 (it) | Concentrati di additivi, adatti all'impiego nella | |
MA27169A1 (fr) | Metabolites de l'acide (3-{ [(4-tertiobutylbenzyl)-(pyridine-3-sulfonyl)-amino]-methyl}-phenoxy)-acetique | |
FR2905070B1 (fr) | Composition cosmetique pour l'eclaicissement ou l'homogeneisation du teint | |
SI1377550T1 (en) | Phenyl heterocyclyl ether derivatives as serotonin re-uptake inhibitors | |
AU2003239581A1 (en) | Difluorothioacetamides of oxazolidinones as antibacterial agents | |
GB0118407D0 (en) | Oxazolidinone derivatives as antibacterial agents | |
FR2856983B3 (fr) | Structure pour flacon de lotion | |
IL173135A0 (en) | Composition for the fluorescent whitening of paper | |
WO2006055663A3 (fr) | Nouvelle utilisation | |
FR2887456B1 (fr) | "composition pour le traitement de la dermite estivale" | |
FR2885300B1 (fr) | Composition topique pour la protection de l'epiderme | |
FR2898057B1 (fr) | Utilisation de composes derives de l'adenine pour le traitement de lupus | |
GB0403352D0 (en) | Bath 'n' easy | |
UA8182S (uk) | Пляшка горілчана «чарочка» | |
WO2005082873A3 (fr) | Nouveau compose 1,4-benzothiazepanes et leurs derives |